Published in Hypertension on May 06, 2013
Effectiveness of adrenalectomy and aldosterone antagonists for long-term treatment of primary aldosteronism. Hypertension (2013) 1.07
Management of hypertension in primary aldosteronism. World J Cardiol (2014) 0.84
Aldosterone and the heart: still an unresolved issue? Front Endocrinol (Lausanne) (2014) 0.79
Effect of Treatment on Body Fluid in Patients with Unilateral Aldosterone Producing Adenoma: Adrenalectomy versus Spironolactone. Sci Rep (2015) 0.79
Long term outcome of Aldosteronism after target treatments. Sci Rep (2016) 0.79
Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients. Circ Cardiovasc Qual Outcomes (2015) 0.78
Outcome of surgical treatment of primary aldosteronism. Langenbecks Arch Surg (2015) 0.76
Treatment of Primary Aldosteronism and Organ Protection. Int J Endocrinol (2015) 0.75
The Challenges of Arterial Hypertension. Front Cardiovasc Med (2015) 0.75
Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight (2017) 0.75
Response to Effectiveness of adrenalectomy and aldosterone antagonists for long-term treatment of primary aldosteronism. Hypertension (2013) 0.75
Effects of low-dose spironolactone combined with irbesartan on cardiac hypertrophy induced by pressure overload in rats. Am J Transl Res (2014) 0.75
Cardiac Dysfunction in Association with Increased Inflammatory Markers in Primary Aldosteronism. Endocrinol Metab (Seoul) (2016) 0.75
Approach to the surgical management of primary aldosteronism. Gland Surg (2015) 0.75
Risk factors for renal impairment revealed after unilateral adrenalectomy in patients with primary aldosteronism. Medicine (Baltimore) (2016) 0.75
Quantitative Value of Aldosterone-Renin Ratio for Detection of Aldosterone-Producing Adenoma: The Aldosterone-Renin Ratio for Primary Aldosteronism (AQUARR) Study. J Am Heart Assoc (2017) 0.75
Primary aldosteronism: a common cause of resistant hypertension. CMAJ (2017) 0.75
Monozygotic twins discordant for primary aldosteronism: a case report. J Hum Hypertens (2017) 0.75
Hypertension outcomes of adrenalectomy in patients with primary aldosteronism: a systematic review and meta-analysis. BMC Endocr Disord (2017) 0.75
Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med (2007) 6.58
Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2008) 6.48
Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension (2006) 4.20
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol (2006) 3.74
Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev (2002) 3.13
The T(-786)C endothelial nitric oxide synthase genotype predicts cardiovascular mortality in high-risk patients. J Am Coll Cardiol (2006) 2.96
Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet (2013) 2.83
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of aldosterone oversecretion in primary aldosteronism patients. J Hypertens (2006) 2.61
Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension (2012) 2.31
Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens (2006) 2.09
The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study. J Am Coll Cardiol (2003) 1.97
Hypertension in acute ischemic stroke: a compensatory mechanism or an additional damaging factor? Arch Intern Med (2003) 1.93
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst (2008) 1.92
Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab (2011) 1.86
Menopause does not affect blood pressure and risk profile, and menopausal women do not become similar to men. J Hypertens (2008) 1.70
Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension (2008) 1.69
Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension (2008) 1.65
Munchausen syndrome: a novel cause of drug-resistant hypertension. J Hypertens (2013) 1.63
C-344T polymorphism of the aldosterone synthase gene and blood pressure in the elderly: a population-based study. J Hypertens (2005) 1.61
Malignancies in β-thalassemia patients: first description of two cases of thyroid cancer and review of the literature. Hemoglobin (2011) 1.57
Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different protocols. Hypertension (2009) 1.57
The white-coat effect is unrelated to the difference between clinic and daytime blood pressure and is associated with greater reactivity to public speaking. J Hypertens (2003) 1.54
Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens (2006) 1.53
Genetic polymorphism of the renin-angiotensin-aldosterone system and arterial hypertension in the Italian population: the GENIPER Project. J Hypertens (2003) 1.52
Renal vein renin measurements accurately identify renovascular hypertension caused by total occlusion of the renal artery. J Hypertens (2002) 1.48
The role of unilateral adrenalectomy in ACTH-independent macronodular adrenal hyperplasia (AIMAH). World J Surg (2008) 1.47
The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J Hypertens (2010) 1.46
Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. Hypertension (2009) 1.45
Endothelial progenitor cells relationships with clinical and biochemical factors in a human model of blunted angiotensin II signaling. Hypertens Res (2011) 1.44
Effect of body weight loss on blood pressure after 6 years of follow-up in stage 1 hypertension. Am J Hypertens (2006) 1.42
Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens (2002) 1.41
Blood pressure control according to new guidelines targets in low- to high-risk hypertensives managed in specialist practice. J Hypertens (2004) 1.41
Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer (2005) 1.39
What is the accuracy of clinic blood pressure measurement? Am J Hypertens (2005) 1.39
Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab (2008) 1.38
Interventional approach to reduce thromboembolic risk in patients with atrial fibrillation ineligible for oral anticoagulation. Ital Heart J (2005) 1.38
Left ventricular structural and functional characteristics in Cushing's syndrome. J Am Coll Cardiol (2003) 1.38
The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Coll Cardiol (2003) 1.33
Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study. J Clin Endocrinol Metab (2005) 1.32
Antioxidant effect of L-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int J Cardiol (2006) 1.30
Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. Clin Endocrinol (Oxf) (2004) 1.29
G-protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism. J Endocrinol (2007) 1.28
Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J Clin Endocrinol Metab (2012) 1.25
Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens (2002) 1.24
High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) (2004) 1.21
Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. J Hypertens (2006) 1.20
Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer (2005) 1.20
Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf) (2007) 1.20
Expression profiles for steroidogenic enzymes in adrenocortical disease. J Clin Endocrinol Metab (2005) 1.19
Is the laparoscopic adrenalectomy for pheochromocytoma the best treatment? Surgery (2007) 1.17
The role of oxidized low-density lipoproteins in atherosclerosis: the myths and the facts. Mediators Inflamm (2013) 1.15
BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience. Clin Chem Lab Med (2010) 1.15
Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension (2007) 1.13
Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: a dose-response study. J Clin Endocrinol Metab (2002) 1.11
Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens (2007) 1.10
Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens (2006) 1.09
Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension (2002) 1.08
Longitudinal Strain and Type 1 Diabetes Mellitus: Are We on the Wrong Track? JACC Cardiovasc Imaging (2015) 1.08
Marriage and nocturnal blood pressure: a complex relationship. J Hypertens (2014) 1.07
Angiotensin II type 1 and type 2 receptor interplay in hypertension: lesson from a human model of vascular hyporeactivity. J Hypertens (2013) 1.07
Chronic kidney disease in hypertension under specialist care: the I-DEMAND study. J Hypertens (2010) 1.07
A kidney tumor in an adolescent with severe hypertension and hypokalemia: an uncommon case--case report and review of the literature on reninoma. Urol Int (2010) 1.07
Extracellular Volume and Cardiac Mechanics: Have We Found a Missing Puzzle Piece? JACC Cardiovasc Imaging (2015) 1.05
Heterogeneity of aldosterone-producing adenomas revealed by a whole transcriptome analysis. Hypertension (2007) 1.04
Low-density lipoprotein cholesterol and mortality in older people. J Am Geriatr Soc (2005) 1.03
Elevated expression of luteinizing hormone receptor in aldosterone-producing adenomas. J Clin Endocrinol Metab (2005) 1.03
Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J Am Coll Cardiol (2003) 1.02
Estimated risk for developing autoimmune Addison's disease in patients with adrenal cortex autoantibodies. J Clin Endocrinol Metab (2006) 1.02
Neurogenic abnormalities in masked hypertension. Hypertension (2007) 0.99
A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet (2013) 0.98
The role of TASK1 in aldosterone production and its expression in normal adrenal and aldosterone-producing adenomas. Clin Endocrinol (Oxf) (2009) 0.98
Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J Hypertens (2012) 0.98
Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing's syndrome: a European multicentric study. J Clin Endocrinol Metab (2014) 0.97
Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis. Clin Endocrinol (Oxf) (2010) 0.97
Adipose tissue as an endocrine organ? A review of recent data related to cardiovascular complications of endocrine dysfunctions. Clin Exp Hypertens (2004) 0.97
Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens (2007) 0.96
The reticulin algorithm for adrenocortical tumor diagnosis: a multicentric validation study on 245 unpublished cases. Am J Surg Pathol (2013) 0.96
BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma. Thyroid (2011) 0.96
Role of nitric oxide concentrations on human sperm motility. J Androl (2004) 0.95
Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol (2011) 0.95
Adiponectin receptor expression in the human adrenal cortex and aldosterone-producing adenomas. Int J Mol Med (2006) 0.95
Coenzyme Q(10) supplementation in infertile men with idiopathic asthenozoospermia: an open, uncontrolled pilot study. Fertil Steril (2004) 0.94
Association between coffee consumption and risk of hypertension. Ann Med (2007) 0.94
Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1. Fam Cancer (2005) 0.94